/AVDL
AVDL Stock - Avadel Pharmaceuticals plc
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$21.48-0.09%
$0.02 (-0.09%) • Jan 13
58
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.83
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).38
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.68
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-6.0%upside
Target: $20.19
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AVDL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$21.27 – $21.69
TARGET (TP)$20.20
STOP LOSS$19.76
RISK/REWARD1:-0.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.30
52W High$23.57
52W Low$6.38
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $169.12M | $27.96M | N/A | N/A | $22.33M |
| Gross Profit | $153.84M | $27.12M | N/A | N/A | $16.59M |
| Gross Margin | 91.0% | 97.0% | N/A | N/A | 74.3% |
| Operating Income | $-42,399,000 | $-137,849,000 | $-98,561,000 | $-85,546,000 | $5.82M |
| Net Income | $-48,832,000 | $-160,276,000 | $-137,464,000 | $-77,329,000 | $7.03M |
| Net Margin | -28.9% | -573.2% | N/A | N/A | 31.5% |
| EPS | $-0.51 | $-2.00 | $-2.29 | $-1.32 | $0.13 |
Company Overview
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
AVDLBeat Rate
29%
Last 17 quarters
Avg Surprise
+12.8%
EPS vs Estimate
Beats / Misses
5/10
2 met exactly
Latest EPS
$0.10
Q3 2025
EPS Surprise History
Q4 23
-17.1%
$-0.41vs$-0.35
Q1 24
-14.3%
$-0.32vs$-0.28
Q2 24
-20.0%
$-0.30vs$-0.25
Q3 24
+17.6%
$-0.14vs$-0.17
Q4 24
+50.0%
$-0.03vs$-0.06
Q1 25
0.0%
$-0.05vs$-0.05
Q2 25
+28.6%
$-0.05vs$-0.07
Q3 25
+400.0%
$0.10vs$0.02
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | $0.09 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.04 | — | — | — |
Q3 2025 | Aug 7, 2025 | $0.02 | $0.10 | +400.0% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.07 | $-0.05 | +28.6% | ✓ BEAT |
Q1 2025 | Mar 3, 2025 | $-0.05 | $-0.05 | 0.0% | = MET |
Q4 2024 | Nov 12, 2024 | $-0.06 | $-0.03 | +50.0% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.17 | $-0.14 | +17.6% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.25 | $-0.30 | -20.0% | ✗ MISS |
Q1 2024 | Mar 4, 2024 | $-0.28 | $-0.32 | -14.3% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.35 | $-0.41 | -17.1% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.39 | $-0.70 | -79.5% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.37 | $-0.48 | -29.7% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $-0.30 | $-0.44 | -46.7% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.22 | $-0.33 | -50.0% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.41 | $-0.50 | -22.0% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.44 | $-0.45 | -2.3% | ✗ MISS |
Q1 2022 | Mar 17, 2022 | $-0.42 | $-0.38 | +9.5% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-0.38 | $-0.38 | 0.0% | = MET |
Q3 2021 | Aug 9, 2021 | $-0.31 | $-0.33 | -6.5% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about AVDL
What is AVDL's current stock price?
Avadel Pharmaceuticals plc (AVDL) is currently trading at $21.48 per share. The stock has moved -0.09% today.
What is the analyst price target for AVDL?
The average analyst price target for AVDL is $20.20, based on 1 analyst.
What sector is Avadel Pharmaceuticals plc in?
Avadel Pharmaceuticals plc operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is AVDL's market cap?
Avadel Pharmaceuticals plc has a market capitalization of $2.08 billion, making it a mid-cap company.
Does AVDL pay dividends?
No, Avadel Pharmaceuticals plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALVO
Alvotech
$4.83
Mkt Cap: $1.5B
ANIP
ANI Pharmaceuticals, Inc.
$82.28
Mkt Cap: $1.8B
BGM
BGM Group Ltd.
$3.65
Mkt Cap: $0.7B
EVO
Evotec SE
$3.87
Mkt Cap: $1.4B
GRDN
Guardian Pharmacy Services, Inc.
$31.26
Mkt Cap: $2.0B
MD
Pediatrix Medical Group, Inc.
$22.17
Mkt Cap: $1.9B
OGN
Organon & Co.
$8.43
Mkt Cap: $2.2B
PAHC
Phibro Animal Health Corporation
$40.46
Mkt Cap: $1.6B
QDEL
QuidelOrtho Corporation
$33.30
Mkt Cap: $2.3B
TLRY
Tilray Brands, Inc.
$9.39
Mkt Cap: $1.0B
Explore stocks similar to AVDL for comparison